Aluminum Hydroxide Adjuvant

BIOLOGICAL3 trials

Sponsors

Shanghai Institute Of Biological Products, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

H7N9 InfluenzaHIV Infections

Phase 1

A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine

CompletedNCT03369808

Shanghai Institute Of Biological ProductsH7N9 Influenza

Start: 2017-12-29End: 2019-11-15Updated: 2024-10-15

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

CompletedNCT03382418

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2017-12-27End: 2019-09-25Updated: 2021-10-08

Phase 2

A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine

CompletedNCT03755427

Shanghai Institute Of Biological ProductsH7N9 Influenza

Start: 2018-11-10End: 2019-11-15Updated: 2024-10-16

Related Papers

Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.

2023-09-092 citations